Praxis Precision Medicines Showcases Innovations in Epilepsy
BOSTON, Sept. 4, 2024 – Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company dedicated to transforming genetic insights into treatments for central nervous system (CNS) disorders, has announced its participation in the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress. This important event will be held from September 7 to 11, 2024, and will gather experts to discuss the latest advancements in epilepsy research.
Steven Petrou, the chief scientific officer and co-founder of Praxis, expressed his excitement about the company’s progress. "We are thrilled to highlight the ongoing advancements in our epilepsy assets, including significant findings from our studies on elsunersen and relutrigine. We are currently enrolling participants in registrational trials for both compounds and are eager to launch our ENERGY program featuring PRAX-628 soon," he stated.
Key Presentations at the European Epilepsy Congress
At this prestigious gathering, Praxis will deliver several presentations that highlight their innovative strategies for treating epilepsy. Attendees are encouraged to visit the Praxis team at booth #441 to learn more about their groundbreaking research findings.
Oral Presentation Schedule
An important oral presentation is set for Tuesday, September 10, from 01:02 p.m. to 01:10 p.m. CEST, during the Pediatric Epileptology session at the Caravaggio venue.
Overview of Poster Presentations
In addition, Praxis will showcase multiple poster presentations from September 8 to 10, 2024, during the afternoon sessions at the Forum venue. Notable presentations include:
- P083: Pharmacokinetics, Tolerability and Cardiac Safety for PRAX-628, a Therapeutic for Focal Onset Seizures.
- P898: A Novel Antisense Oligonucleotide Treatment for Early Onset SCN2A Developmental and Epileptic Encephalopathy.
- P908: EMBOLD Clinical Trial of PRAX-562 for Developmental and Epileptic Encephalopathies.
- P074: A Translational Concordance Framework for Predicting Seizure Models.
- P339: EEG Composite Techniques for Detecting Drug Effects in Epilepsy.
Innovative Treatments for Epilepsy
Praxis is at the forefront of developing unique therapies such as relutrigine and PRAX-628, which specifically target neurological channels to improve patient outcomes. Relutrigine has shown promising results in reducing seizure activity across various mouse models and has demonstrated good tolerability in Phase 1 studies. It has also received Orphan Drug and Rare Pediatric Disease designations, highlighting its potential in treating severe developmental and epileptic encephalopathies.
Furthermore, PRAX-628 is being developed as a once-daily oral treatment. Preclinical data suggest its efficacy surpasses that of existing treatments, positioning it as a potential best-in-class option for managing focal seizures.
About Elsunersen (PRAX-222)
Another key focus for Praxis is Elsunersen, an antisense oligonucleotide aimed at reducing SCN2A gene expression, specifically targeting early-onset SCN2A developmental and epileptic encephalopathy. Research indicates that it not only reduces seizures but also improves overall functionality in affected patients. Elsunersen has received both FDA Orphan Drug and Rare Pediatric Designations, underscoring its vital role in therapeutic strategies.
About Praxis Precision Medicines
Praxis Precision Medicines is committed to developing pioneering therapies for CNS disorders characterized by an imbalance in neuronal excitation and inhibition. With a diverse portfolio that includes multiple clinical-stage candidates, Praxis continues to harness genetic insights to create innovative treatments for neurological disorders.
To learn more about their groundbreaking work and stay updated on their latest developments, individuals are encouraged to visit the Praxis website and follow them on social media platforms.
Frequently Asked Questions
1. What is the purpose of Praxis’s presentations at the Congress?
Praxis aims to showcase the latest advancements in their epilepsy research and highlight their innovative treatment options.
2. What are the key compounds being presented by Praxis?
Key compounds include relutrigine, PRAX-628, and Elsunersen, which target various forms of epilepsy and related disorders.
3. Where can attendees find Praxis during the Congress?
Attendees can visit Praxis at booth #441 for discussions and insights about their research.
4. What designations have been awarded to the compounds developed by Praxis?
Compounds like Relutrigine and Elsunersen have received Orphan Drug Designation and Rare Pediatric Disease Designation from regulatory agencies.
5. How does Praxis use genetic insights in their research?
Praxis translates genetic insights into the development of therapies aimed at correcting neuronal excitation-inhibition imbalances in CNS disorders.
